|
WO2021080427A1
|
|
Chimeric polypeptide for regulating immune cells
|
|
WO2021080421A1
|
|
Novel drug combinations for treatment of a carcinoma
|
|
WO2021025554A1
|
|
Combination comprising an activator of the glucocorticoid receptor and an inhibitor of ifg-1 signaling for carcinoma treatment
|
|
WO2021015619A1
|
|
Progression markers for colorectal adenomas
|
|
WO2021010824A1
|
|
Oral disodium pyrophosphate for use in reducing calcification
|
|
WO2020256548A1
|
|
Sodium thiosulfate gel for preventing or reducing hearing loss
|
|
WO2020117052A2
|
|
Ezh2- fgfr inhibition in cancer
|
|
WO2020094569A1
|
|
Method for determining cellular composition of a tumor
|
|
WO2020002592A1
|
|
Traf2 inhibitors for use in the treatment of a cancer
|
|
WO2020005068A2
|
|
Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
|
|
EP3657167A1
|
|
Method of predicting responsiveness of a gastrointestinal cancer patient to a chemotherapy treatment
|
|
EP3650556A1
|
|
Method for determining cellular composition of a tumor
|
|
EP3747438A1
|
|
Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
|
|
NL2021185B1
|
|
Combination Therapy and Use Thereof for Treating Cancer
|
|
WO2018217087A1
|
|
Novel stool-based protein biomarkers for colorectal cancer screening
|
|
NL2020422B1
|
|
Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
|
|
NL2020329B1
|
|
Surgical instrument and surgical system
|
|
NL2019814B1
|
|
Methods for producing a MHC multimer.
|
|
EP3516390A1
|
|
Manipulation of immune activity by modulation of expression
|
|
US2019216850A1
|
|
Oral pyrophosphate for use in reducing tissue calcification
|
